Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma.
aerobic glycolysis
cholangiocarcinoma
glucose metabolism
metabolic reprogramming
warburg effect
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
11
2019
accepted:
12
03
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) is one of the most lethal cancers, and its rate of occurrence is increasing annually. The diagnoses of CCA patients remain elusive due to the lack of early symptoms and is misdiagnosed as HCC in a considerable percentage of patients. It is crucial to explore the underlying mechanisms of CCA carcinogenesis and development to find out specific biomarkers for early diagnosis of CCA and new promising therapeutic targets. In recent times, the reprogramming of tumor cells metabolism has been recognized as a hallmark of cancer. The modification from the oxidative phosphorylation metabolic pathway to the glycolysis pathway in CCA meets the demands of cancer cell proliferation and provides a favorable environment for tumor development. The alteration of metabolic programming in cancer cells is complex and may occur via mutations and epigenetic modifications within oncogenes, tumor suppressor genes, signaling pathways, and glycolytic enzymes. Herein we review the altered metabolism in cancer and the signaling pathways involved in this phenomena as they may affect CCA development. Understanding the regulatory pathways of glucose metabolism such as Akt/mTOR, HIF1α, and cMyc in CCA may further develop our knowledge of this devastating disease and may offer relevant information in the exploration of new diagnostic biomarkers and targeted therapeutic approaches for CCA.
Identifiants
pubmed: 32318579
doi: 10.3389/fmed.2020.00113
pmc: PMC7146077
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
113Informations de copyright
Copyright © 2020 Pant, Richard, Peixoto and Gradilone.
Références
J Biol Chem. 2000 Jul 21;275(29):21797-800
pubmed: 10823814
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Br J Cancer. 2015 Mar 17;112(6):1042-51
pubmed: 25742482
Curr Opin Genet Dev. 2007 Feb;17(1):71-7
pubmed: 17208433
Mol Med Rep. 2015 Sep;12(3):3265-3272
pubmed: 26018028
Dis Model Mech. 2013 Mar;6(2):281-92
pubmed: 23520144
Cell Physiol Biochem. 2017;41(3):921-932
pubmed: 28222430
Front Oncol. 2017 Mar 29;7:58
pubmed: 28405578
Genes Dev. 2001 Apr 1;15(7):807-26
pubmed: 11297505
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
Ann Nucl Med. 2008 Jan;22(1):83-6
pubmed: 18250992
Clin Cancer Res. 2009 Nov 1;15(21):6479-83
pubmed: 19861459
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
J Biol Chem. 2016 Jan 22;291(4):1841-53
pubmed: 26631731
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Physiology (Bethesda). 2010 Apr;25(2):85-101
pubmed: 20430953
Cancer Res. 2000 Nov 1;60(21):6178-83
pubmed: 11085542
J Hepatol. 2017 Dec;67(6):1194-1203
pubmed: 28733220
J Cell Biol. 2006 Dec 18;175(6):845-7
pubmed: 17158959
Dig Liver Dis. 2015 Jul;47(7):590-6
pubmed: 25912843
Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):686-699
pubmed: 28161329
Cell Death Discov. 2015 Nov 23;1:15057
pubmed: 27551483
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Biochem Pharmacol. 2019 Aug;166:174-184
pubmed: 31085159
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
Mol Biol Rep. 2015 Apr;42(4):841-51
pubmed: 25689954
Int J Mol Sci. 2018 Aug 19;19(8):
pubmed: 30126252
Mol Cancer. 2017 Apr 13;16(1):79
pubmed: 28407774
Liver Int. 2013 May;33(5):771-9
pubmed: 23445369
Oncotarget. 2015 Jan 20;6(2):651-61
pubmed: 25528771
Cancer Treat Rev. 2019 Jan;72:45-55
pubmed: 30476750
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
World J Surg Oncol. 2014 Mar 31;12:78
pubmed: 24679073
Mol Med Rep. 2019 Feb;19(2):783-791
pubmed: 30535469
Cell Res. 2018 Mar;28(3):265-280
pubmed: 29219147
Nat Med. 2004 Jun;10(6):594-601
pubmed: 15156201
Oncol Lett. 2019 Jun;17(6):5275-5282
pubmed: 31186744
Curr Cancer Drug Targets. 2013 Mar;13(3):245-51
pubmed: 23297826
Recent Results Cancer Res. 2016;207:39-72
pubmed: 27557534
Exp Mol Med. 2018 Sep 21;50(9):127
pubmed: 30242145
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059435
Curr Top Med Chem. 2018;18(6):444-453
pubmed: 29788890
Neoplasia. 2019 May;21(5):429-441
pubmed: 30933885
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Cell. 2003 Mar 7;112(5):645-57
pubmed: 12628185
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1439-44
pubmed: 21940327
Biochim Biophys Acta. 2011 Jun;1807(6):552-61
pubmed: 20955683
Cancer Med. 2019 May;8(5):2380-2391
pubmed: 30993888
Hum Pathol. 2014 Aug;45(8):1610-7
pubmed: 24824030
Histol Histopathol. 2017 May;32(5):503-510
pubmed: 27615379
Cell Death Dis. 2018 Apr 27;9(5):466
pubmed: 29700317
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
Clin Cancer Res. 2019 Jan 1;25(1):403-413
pubmed: 30084835
Curr Mol Med. 2018;18(6):343-351
pubmed: 30411685
Acta Oncol. 2017 Apr;56(4):503-515
pubmed: 28358664
FEBS Open Bio. 2016 Jun 08;6(7):735-41
pubmed: 27398313
Oncotarget. 2016 Jun 21;7(25):38908-38926
pubmed: 26918353
Hepatology. 2008 Jul;48(1):308-21
pubmed: 18536057
Front Oncol. 2018 May 15;8:160
pubmed: 29868481
Cell Stress Chaperones. 2016 Jul;21(4):553-62
pubmed: 27072803
Expert Opin Ther Targets. 2009 Dec;13(12):1411-27
pubmed: 19874261
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63
pubmed: 9192621
Oncol Rep. 2018 Feb;39(2):843-850
pubmed: 29251327
Cancer Chemother Pharmacol. 2016 May;77(5):963-72
pubmed: 27011212
Clin Cancer Res. 2012 Oct 15;18(20):5546-53
pubmed: 23071356
Int J Clin Exp Pathol. 2018 Oct 01;11(10):4950-4956
pubmed: 31949571
Hepatology. 2011 Jul;54(1):173-84
pubmed: 21488076
Biochim Biophys Acta. 2011 Jun;1807(6):534-42
pubmed: 20849810
Biomed Res Int. 2014;2014:616850
pubmed: 24745019
Cell Commun Signal. 2019 Mar 12;17(1):23
pubmed: 30866966